Background
==========

The therapeutic options indicated for patients with breast cancer continue to be based, principally, on clinical-pathology criteria. The incorporation of new immunohistochemistry and molecular biology markers into the diagnosis has advanced the knowledge of potential markers of prognosis and prediction of response to endocrine therapy in breast cancer. One of the biomarkers most used is the expression of estrogen and of progesterone receptors (ER and PR, respectively) \[[@B1]\]. However, only 2/3 of the patients diagnosed with breast cancer express ER at diagnosis (ER+), while the other 1/3 of the cases do not express the receptors (ER-), and which is associated with non-differentiated tumors, with high cell proliferation index, poor response to endocrine therapy and poor prognosis \[[@B2]\]. Some tumors which are ER + at the time of diagnosis become ER- in the course of the clinical evolution of the disease \[[@B3]\]. Also, 30-40% of the ER + patients will develop resistance to the anti-estrogen treatment and which will favor the appearance of distant metastases, and death.

To date, the molecular bases of the response to endocrine therapy are poorly understood. Recent studies have shown that heterogeneity of response and prediction of response to chemotherapy and sensitivity to hormone therapy is based on "molecular portraits" \[[@B4],[@B5]\]. However, the list of genes implicated in prognosis may or may not necessarily relate to the clinical results obtained in response to treatment \[[@B6]\] and, as such, warrants further investigation.

To date, methylation of DNA is known as an epigenetic phenomenon which plays a decisive role in the regulation of signal translation processes. Under physiological conditions, this epigenetic event influences which genes are activated during the process of normal cell differentiation \[[@B7]\], the maintenance of "genetic imprinting" \[[@B8]\], inactivation of the X chromosome \[[@B9]\], genetic transcription repression \[[@B10]\] and the suppression of regions of parasite DNA \[[@B11]\]. However, these epigenetic events, when aberrant, have a determining role in the development of malignant tumor processes \[[@B12],[@B13]\] and, as well, the suggestion is of an involvement in resistance to chemotherapy, radiotherapy and hormone therapy \[[@B14]\].

ER role is key since up to 1/3 of the patients who do not express ER (i.e. ER-), rarely respond to hormone treatment \[[@B15]\]. ER is coded-for by the *ESR1* gene located at chromosome 6q25.1, the promoter region of which contains a linked CpG sequence in exon 1. In breast cancer cell lines such as MCF-7, T47-d and ZR75-1 \[[@B16]\] that express ER (i.e. ER+) this region is observed to be non-methylated, and is similar to that occurring in normal tissue. However, in cells lines from ER- breast cancer, such as MDA-MB-231, MDA-MB-435, MDA-MB-468, Hs578t and MCF-7/Adr, methylation is observed in \>50% of cases \[[@B17]\]. Hence, determining the methylation status of the promoter region of the *ERS1* could be critical since it represents one of the mechanisms by which the loss of ER expression is associated with breast cancer diagnosis. Blocking this process of methylation could be important since this could lead to patients who are resistant to hormone treatment becoming sensitive to hormone treatment \[[@B18]\].

Based on the literature, as well as on the experience in our own research group \[[@B19]-[@B21]\], we designed the present study to assess whether ER- expression in tumor tissue correlates with methylated status of the *ESR1* in serum i.e. a mechanism of gene silencing that can explain, at least in part, the lack of hormone therapy efficacy in breast cancer. Also, we sought insight into fcDNA methylation and tumor phenotypes: Luminal A (LA), Luminal B (LB), Triple negative (TN) and Her2 +.

Methods
=======

Study population
----------------

A total of 110 patients diagnosed as having non-metastatic breast cancer in the *Hospital Universitario Virgen de las Nieves de Granada* (Spain) were included in the study. Patient characteristics are summarized in Table [1](#T1){ref-type="table"}. The study was approved by the Institutional Ethics Committee of the *Hospital Universitario Virgen de las Nieves de Granada*, and written informed consent was obtained from all study participants.

###### 

Demographic characteristics of the breast cancer patients

  **Characteristic**                                             **Cases**     **SD**
  --------------------------------------------- ---------------- ------------- --------
  Mean age; years (range)                                        58 (32--88)   12.4
  Mean age at menarche; years (range)                            13 (10--17)   1.4
  Mean age at menopause; years (range)                           49 (39--59)   3.8
  Menopausal status                                                             
                                                Pre-menopause    30.8%          
                                                Post-menopause   69.2%          
  Mean age at first live birth; years (range)                    25 (18--41)   3.9
  Mean age at last live birth; years (range)                     32 (20--42)   5.2
  Breastfeeding                                                                 
                                                Yes              82 (76.6%)     
                                                No               23 (21.5%)     
  Breastfeeding; months (range)                                  6 (1--36)     5.1

SD: standard deviation.

Collection and processing of samples and DNA preparation
--------------------------------------------------------

Blood samples (10 ml) were taken by venipuncture from all the study patients on introduction into the study and before the administration of any medication. The blood samples were collected into EDTA Vacutainer® tubes and coded before processing to ensure blinding with respect to sample provenance. The samples were transported at room temperature to the laboratory, centrifuged at 2000 g for 10 min at room temperature, the plasma obtained was distributed in 1 ml aliquots into 1 ml criotubes, and stored at -80°C until needed for processing.

\- DNA isolation: DNA from plasma samples (2 ml per column) was obtained using QIAmp DNA Blood kit (QIAGEN Inc., CA) according to manufacturer's recommendations. A final elution volume was 200 μl and the extracted DNA was quantified spectrophotometrically. The amount of DNA recovered, measured as μg/sample, was 0.431 ± 0.019 (mean value ± standard error of the mean). The fcDNA samples were stored at −80°C until needed for analysis.

Quantitative Methylation Specific (QMS) polymerase chain reaction (PCR) analysis
--------------------------------------------------------------------------------

\- DNA bisulfite modification: Identical DNA sequences that differ only in methylation status can be amplified by means of Quantitative Methylation Specific PCR (QMS-PCR) \[[@B22]\]. Reagents required for the bisulfite modification of fcDNA were supplied in the CpGenome™ DNA Modification Kit (Intergen, MA). The process was performed according to manufacturer's recommendations. Sufficient fcDNA can be recovered to perform QMS-PCR from an amount of starting material as small as 0.001 μg. In brief, 100 μl of extracted fcDNA was treated with sodium bisulfite for 16 h, thereby converting all unmethylated cytosines to uracils, but leaving methylcytosines unaltered. After purification, the fcDNA obtained was dissolved in 20 μl of TE buffer and the modified DNA was spectrophotometrically quantified. Efficiency of fcDNA recovery after bisulfite modification was around 55% (data not shown). Recovered bisulfite-treated fcDNA (1 μl) was used in each well for SYBR green reaction. Modified DNA of standards and samples are stable for at least 2 months at −80°C. A sample of bisulfite-modified universally-methylated genomic DNA, (CpGenomeTM Universal Methylated DNA, Intergen, New York, NY) treated in the same way as patient samples and the concentration adjusted, after modification, to 2 μg/ml (quantified spectrophotometrically), served as internal standard in preparing serial dilutions (from 1 to 1/128 with MiliQ water) to construct a standard curve for Real-Time QMS-PCR. Each multi-well plate contained patient samples, serial dilutions of completely methylated DNA for constructing calibration curves, positive controls, and two wells with water used as negative controls ("blanks"). In all experiments, correlation coefficients for the calibration curves were \>0.98, slopes ranged from 3.2 to 3.4, and PCR efficiencies were around 100%.

As found by other authors \[[@B19],[@B20],[@B23],[@B24]\], some gene promoters were frequently observed to have methylated DNA in the plasma of cancer patients, albeit traces of methylated DNA may also be found in plasma of patients without cancer when highly sensitive quantitative techniques are used. Hence, cut-off points for the *ESR1* methylated promoter was established from the receiver operating characteristics (ROC) curves i.e. selecting values that gave the maximal likelihood ratio (in current case the cut-of value was 0.02 relative units) \[[@B20]\]. Assuming levels of methylation of *ESR1* \< 0.02 relative units, "test of methylation (−)", was indicative of absence of the disease (physiological) while levels of methylation of *ESR1* \> 0.02 relative units measured in the plasma "test of methylation (+)" was indicative of presence of breast cancer (pathological level of methylation). Once the distribution of cases was established in the two groups as "test of methylation (−)" and "test of methylation (+)", the study proceeded to assess whether this characteristic was associated with the phenotype ER(+) and ER(−) in tumor tissue.

Using a method developed previously in our group \[[@B20],[@B21]\], Quantitative Methylation Specific PCR (QMS-PCR) was performed with the iQ SYBR-Green Supermix Kit (BioRad Laboratories; Hercules, CA) according to the manufacturer's protocol. The sequences of the primers for *ESR1* were selected from previous publications: *ESR1* Genebank 2099 location to transcription start Promoter A \[[@B25]\]. The fluorescence value corresponding to each sample was converted into relative units of universally methylated DNA (umDNA; μg/mL) using the corresponding calibration curve adjusted by the software program of the QMS-PCR equipment. The PCR reaction was conducted in 96-well plates which contained: patient samples, successive dilutions for the calibration curve, 2 positive controls, and 2 negative controls or "blanks" (without DNA). In all cases the correlation coefficients for the calibration curves were ≥ 0.98, the linear slope was between 3.02 and 3.2, and the PCR efficacy was between 85 and 110%.

Immunohistochemical staining for ER, PR and HER2 expression in tumor tissue
---------------------------------------------------------------------------

Starting with surgically excised tissue preserved in formol, tumor pieces were embedded in paraffin and processed for staining with eosin-hematoxylin. ER and PR expression were evaluated in tumor tissue using the DAKO HORIZON automatic processor (Techmate Horizon). Monoclonal antibody kits were purchased from the manufacturer (DAKO M 7047 Clone 185 for ER and DAKO M 3569 Clone 636 for PR) and used according to the manufacturer's instructions. Nuclear staining indicates positive or negative. Positivity is expressed as intensity of staining and graded as weak (+) moderate (++) and strong (+++), and as percentage of cells stained. Subsequently, HER2 amplification in the tumor sample was with the DAKO K5206 kit. In those cases with HER2 (++), further analysis was with FISH using the DAKO K 5331, HER FISH PharmDxTM kit and hybridized in the DAKO HYBRIDIZER.

Statistical methods
-------------------

The data obtained were analyzed using the following statistical tests: 1) description of the demographic and clinical-pathology variables using means, medians, percentiles, ranges and standard deviations; 2) relationships between ER expression in tumor and quantitative specimen level of *ESR1* methylation using Chi-square (and Fisher's exact) test.

Results and discussion
======================

The demographic and clinical-pathology characteristics of the participants at study entry are summarized in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. The cut-off points for *ESR1* methylated promoter in plasma samples were established from the ROC curves, selecting values that gave the maximal likelihood ratio of 0.02 relative units for *ESR1.* From our results previously obtained \[[@B20]\], we assume that levels of methylation of *ESR1* \>0.02 relative units are indicative of the presence of disease (test "+" indicating breast cancer and pathologic level of methylation *ESR1*) whereas level of methylation \<0.02 relative units indicating absence of disease (test "--" indicating no presence of breast cancer and physiologic level of methylation *ESR1*). Subsequently we sought correlations between methylation levels of the *ESR1* promoter in the fcDNA samples and the absence of transcription and, in turn, with the lack of ER expression in tumor tissue.

###### 

Clinico-pathological characteristics of the breast cancer patients

  **Characteristic**                                   **Cases**   **% of total**
  -------------------- ------------------------------- ----------- ----------------
  Histological type                                                 
                       Invasive ductal carcinoma       82          74.5
                       Invasive lobulillar carcinoma   10          9
                       Invasive mixed carcinoma        7           6.3
                       Others                          11          10
  Histological grade                                                
                       Grade I                         20          18.7
                       Grade II                        40          37.4
                       Grade III                       35          32.7
                       Unknown                         12          11.2
  Pathological T                                                    
                       T1                              64          58
                       T2                              43          39
                       T3                              3           2.7
  Pathological N                                                    
                       N0                              75          68
                       N1                              35          32
                       N2                              0           0
  Luminal phenotype                                                 
                       Luminal A                       39          36.4
                       Luminal B                       22          20.5
                       Triple Negative                 15          14
                       Her2-neu                        10          9.3
                       Unknown                         21          19.6

Using Chi-square (and Fisher's exact) test we studied the relationship between a positive test value for *ESR1-*DNA promoter methylation in plasma sample and ER- status in excised tumor samples from patients with breast cancer (p \< 0.05). Similarly, we checked for correlations between negative test value for *ESR1 vs.* ER + in tumor tissue and observed that the relationship was statistically significant (p \< 0.05). Results obtained showed an association between presence of methylated *ESR1* in fcDNA from patients with breast cancer and ER- status in tumor, an observation that would be expected if promoter methylation leads to silencing of gene expression, and *vice versa*.

Similarly, we investigated the relationship between the gene expression silencing mechanism (using methylation of the *ESR1* promoter i.e. epigenetic silencing) and the luminal phenotype of the tumor tissue; the hypothesis being that the predominant role of methylation is gene silencing (i.e. restricted expression) in the tumor. The Chi-square (and Fisher's exact) test showed a significantly (p \< 0.05) higher percentage of *ESR1* promoter methylation in those phenotypes with poorer prognosis i.e. 80% of the triple negative patients and 60% of patients with HER2 compared to 28% and 36% of patients with phenotypes of better prognosis such as luminal A and luminal B, respectively (Table [3](#T3){ref-type="table"}, Figure [1](#F1){ref-type="fig"}).

###### 

**Percentage*ER*hypermethylation in relation to tumor phenotype**

  ***Test result***    **Luminal A**   **Luminal B**   **Triple negative**   **HER2(+)**   **P**                       
  -------------------- --------------- --------------- --------------------- ------------- ------- ------- --- ------- --------
  *(−) ESR1 \< 0.02*   28              (71%)           14                    (64%)         3       (20%)   4   (40%)   \<0.05
  *(+) ERS1 \> 0.02*   11              (28%)           8                     (36%)         12      (80%)   6   (60%)   \<0.05

![Histogram showing breast cancer subtype of poorer prognosis (TN and Her2) have higher percentage of ESR1-DNA promoter methylation \> 0.02 relative units, while those phenotypes with better prognosis (luminal A and luminal B) the percentage of ESR1-DNA promoter methylation is \< 0.02 relative units.](1471-2407-14-59-1){#F1}

Based on these findings, we analyzed whether there could be subgroups of patients within each luminal phenotype such that a methylation profile could explain, at least in part, why some cases develop distant metastases despite having a good prognostic phenotype. We observed that, within each subgroup segregated with respect to *ESR1* methylation in the fcDNA sample, there was a tendency towards a lower survival at 4.5 years of follow-up in each phenotype that had methylated *ESR1* (*ESR1* methylation level \>0.02) compared to the subgroup in which the *ESR1* methylation level was \<0.02. However, these differences were not statistically significant, perhaps because of the small number of cases (Table [4](#T4){ref-type="table"}).

###### 

Differences in presentation of aberrant ER methylation within the luminal phenotype subgroups

  **Phenotype**         **N**   **OS at 5 years**   **P**
  --------------------- ------- ------------------- -------
  *ER* non-methylated                                
    Luminal A           28      93%                 NS
    Luminal B           14      92%                 NS
    Triple Negative     3       80%                 NS
    Her2                4       75%                 NS
  *ER* methylated                                    
    Luminal A           11      82%                 NS
    Luminal B           8       86%                 NS
    Triple negative     12      75%                 NS
    Her2                6       67%                 NS

OS: overall survival.

It has been well documented that the ER expression in tumor tissue of breast cancer represents one of the principal prognostic factors of long-term survival, and is predictive of the disease response to hormone therapy. As such, the patients with tumors that are ER + are associated with a more favorable prognosis and the hormonal treatment of which is based on tamoxifen and/or aromatase inhibitors. However, in those patients that present tumors with ER-, the hormone treatment has little or no therapeutic value but there is an element of impact on the prognosis of the disease i.e. ER- is associated more frequently with those cases in which the course of the disease is more adverse. Around 25% of breast cancer patients do not express ER at the time of diagnosis and, as such, are resistant to hormonal therapy \[[@B2]\]. Also, in some cases the initial expression of ER + can change to ER- and negatively impact on the long-term course of the disease due to loss of sensitivity to the hormonal treatment \[[@B26]\]. Further research is warranted to explain this finding of change in phenotype \[[@B27]\].

In our literature search, we did find a few studies that correlated the epigenetic profile of methylation and its relationship with ER expression status but no study correlating the methylation with luminal phenotype. There have been earlier studies that investigated the role of methylation of various genes in search of independent markers of prognosis in breast cancer \[[@B28]\]. However, methylation of the promoter region of the *ESR1* gene has received little attention in relation to the absence of ER expression in the corresponding tumor. Authors such as Widschwendter *et al.*\[[@B29]\] described a significant relationship (p = 0.015) between the *APC* methylation status and hormonal receptor status predictors in patients with breast cancer. Others studies, such as that by Yang *et al.*\[[@B30]\], suggested that, in ER + patients, there may be a higher frequency of hypermethylation of the promoter of the *Twist* gene, while methylation of the *CDH1* gene occurs with higher frequency in patients the ER- tumors. Recent articles suggest that the hypermethylation of this gene promoter occurs predominantly in triple negative breast cancer \[[@B31]\]. This hypothesis is contested by other authors \[[@B32]\].

In the present study of cases in which we observed hypermethylation of the *ESR1* promoter in plasma of the patients with breast cancer, we undertook an analysis of epigenetic signal silencing of the *ESR1* gene in patients segregated with respect to luminal phenotypes, to the histopathology of the tumor, and to ER protein expression in the tumor. We evaluated *ESR1*-fcDNA methylation in peripheral plasma in relation to ER expression in tumor tissues. The results showed that the methylation of *ERS*1-fcDNA was correlated significantly with the absence of ER protein expression in the tumor, and *vice versa* (p = 0.018). This result is in accordance with that described by Lapidus *et al.* and Ottaviano *et al.*\[[@B18],[@B33]\] in breast cancer cell lines. Essentially, these authors described that the promoter located in exon 1 of the *ESR1* gene is observed to be highly methylated in the cell lines that do not express ER protein and, conversely, is not methylated in normal breast tissue as well as in the cell lines of breast cancer that express functioning estrogen receptors.

With respect to the luminal phenotype and *ESR1* methylation status, we observed that, in those cases with the better prognosis phenotypes (luminal A and luminal B) the predominant result of the evaluation of *ESR1-*fcDNA methylation was negative i.e. there was a correlation between ER expression and better prognosis while, in the phenotype with poor prognosis (Her2-neu and triple negative), the evaluation was predominantly positive (p \< 0.05). Further analysis of each luminal phenotype with respect to methylated *ESR1* \>0.02 relative units *versus* methylated *ESR1* \<0.02 relative units, showed that, within each subgroup, those that presented methylated *ESR1*(and as such not expressing ER receptors) had a tendency towards shorter overall survival than those with a methylated *ESR* level *\<* 0.02 relative units*.* Hence, it appears that the molecular variant of the methylated promoter region of the *ESR1* gene carries prognostic information that is additional to the prognostic factors that are currently used in the breast cancer clinic.

From the above observations, the most relevant of the results obtained is that methylation, as an epigenetic event, can be one of the mechanisms implicated in the non-expression of ER in the tumor. We observed significant correlation between *ESR1* DNA methylation in peripheral blood and silencing of ER expression in the tumor, and *vice versa*. This finding is of considerable interest especially since we observed, as well, the correlation between *ESR1*-fcDNA methylation and the ER expression in relation to tumor phenotype. The greater expression of the estrogen receptors in the phenotypes that are known to have a better prognosis (LA and LB) while showing significantly lower levels of *ESR1* in peripheral blood. This contrasts with those phenotypes in which the ER expression is low or not present which, in turn is associated with poorer prognosis (triple negative and Her2). The mechanisms involved in the absence of ER expression are not known, and neither are the reasons for non-response to hormonal treatment. Of note, as well, is that tumors that express ER at the time of diagnosis can cease expressing ER over the time-course of the disease. Perhaps one of the causal events in the absence of ER expression (and its negative impact on the clinical evolution of the disease) is that tumors expressing ER at the time of diagnosis are methylated. In studies conducted to date, the known genetic alterations do not fully explain the processes but, based on the results from our study, perhaps methylation is the key to explaining, at least in part, some of the observations. Also, given that methylation is a reversible event, analyzing this reversibility can be useful in identifying the crucial point in the success, or otherwise, of hormonal treatment of breast cancer.

Conclusions
===========

Our results indicate that the silencing of gene expression by methylation of the promoter region of the *ESR1* gene of the estrogen receptor has an important role in the expression of the protein for which this gene codes (i.e. the estrogen receptor) in the primary tumor. The methylation of ESR1 in peripheral bold correlates significantly with the non-expression of ER in excised tumor tissue. As such, this measurement may add prognostic value in identifying luminal phenotypes with poor prognosis and, as well, those with potentially greater resistance to hormonal treatment. The protein is absent in ER- tumors when methylation occurs in the *ESR1* promoter, and *vice versa*. These data demonstrate that analysis of methylation in the DNA from peripheral circulation (fcDNA) can help in determining prognosis or in predicting response to certain types of treatment. Of more importance, perhaps, is that since methylation is a reversible event, its modulation can constitute a future therapeutic target.

Reversal of methylation status and, as such, the genetic expression resulting from this mechanism, could cause a recovery of function of those genes responsible for the regulation of the normal cell cycle which, as a result of an alteration in the methylation pattern, are abnormally silenced. This could be of considerable interest because such an easily measured analyte (*ESR1* DNA methylation in peripheral blood) can serve as biomarker, and probable therapeutic target against breast cancer.
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